0JAV Stock Chart & Stats
$106.54
-$1.37(-1.29%)
At close: 4:00 PM EDT
$106.54
-$1.37(-1.29%)
Day’s Range― - ―
52-Week Range$91.59 - $214.00
Previous CloseN/A
Volume538.00
Average Volume (3M)1.20K
Market Cap
$21.37B
Enterprise Value$34.76K
Total Cash (Recent Filing)$1.16B
Total Debt (Recent Filing)$36.37M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Oct 22, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.11
Shares Outstanding216,752,460
10 Day Avg. Volume559
30 Day Avg. Volume1,195
Financial Highlights & Ratios
PEG Ratio-1.80
Price to Book (P/B)50.31
Price to Sales (P/S)61.31
P/FCF Ratio-38.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$200.44Price Target Upside88.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)-2.61
Revenue Forecast (FY)$1.71B
Bulls Say, Bears Say
Bulls Say
BRINSUPRI Commercial Launch MomentumA rapid, high-volume launch with accelerating new patient starts and materially upgraded full-year guidance demonstrates durable commercial adoption and prescriber penetration. Sustained quarterly starts and strong launch metrics indicate lasting revenue base potential as the product moves from early uptake to steady-state sales.
High And Improving Gross MarginsVery high and improving product gross margins reflect favorable product economics and improving gross-to-net dynamics. Durable margin strength provides operating leverage as revenue scales, improving the company’s ability to fund R&D and SG&A without proportional margin erosion over the medium term.
Stronger Balance Sheet And Cash RunwayMaterial deleveraging and a sizeable cash position reduce solvency risk and extend runway to execute launches and Phase III programs. Lower net debt and positive equity provide strategic flexibility to invest in commercialization and trials while targeting cash‑flow positivity without near‑term capital raises.
Bears Say
Heavy Cash Burn And Negative Free Cash FlowLarge negative operating and free cash flows create persistent runway pressure despite current cash balances. Continued high cash burn from launches and Phase III programs risks requiring additional financing or cutbacks if commercial uptake or reimbursement outcomes slow, making sustainability conditional on execution.
Deep Ongoing Operating LossesEven with accelerating revenue, operating and net losses are severe enough to keep returns strongly negative. Achieving durable profitability requires sustained scale, controlled SG&A/R&D growth, and preservation of gross margins; failure on any front prolongs cash consumption and delays breakeven.
Reimbursement And Execution RiskRevenue outlook depends on favorable payer access, regulatory approvals, and stable GTN trends. European payer constraints, potential GTN increases, milestone obligations, and optimistic uptake assumptions create structural execution risk that could materially reduce net realized revenue and slow path to self-funded growth.
Insmed News
0JAV FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest share price was $91.59 and its highest was $214.00 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $21.37B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Oct 22, 2026 which is in 76 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Aug 06, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.672 by $0.612.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Insmed dividends here
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -0.47.
How many shares outstanding does Insmed have?
Insmed has 216,752,460 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.672. Following the earnings report the stock price went up 30.817%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in GB:0JAV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$200.44 (88.14% Upside)
$200.44 (88.14% Upside)
Blogger Sentiment
Bullish
GB:0JAV Sentiment 88%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.15%
Trailing 12-Months
Company Description
Insmed
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
0JAV Company Deck
0JAV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial execution and materially improved financial and clinical momentum — highlighted by BRINSUPRI’s historic launch ($309.2M Q2, raised FY guidance to $1.25B–$1.4B, peak >$7B), solid ARIKAYCE performance ($116.3M, +8% YoY) and compelling TPIP clinical data with upgraded peak potential (> $6B). Management emphasized a healthy cash position (~$1.2B) and a clear path to cash-flow positivity in 2027. Offsetting risks include higher near-term operating spend (R&D and SG&A +38% YoY), European reimbursement headwinds, milestone payments (~$50M H2 2026), and reliance on optimistic assumptions (diagnosis expansion, regulatory success, pricing). Overall, the positive commercial results, clinical readouts and funding runway substantially outweigh the noted operational and market uncertainties.View all GB:0JAV earnings summaries0JAV Stock 12 Month Forecast
Average Price Target
$200.44
▲(88.14% Upside)